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Abstract
The pentamidine analog PA-6 was developed as a specific inward rectifier
potassium current (IK1) antagonist, because established inhibitors either lack
specificity or have side effects that prohibit their use in vivo. We previously
demonstrated that BaCl2, an established IK1 inhibitor, could prolong action
potential duration (APD) and increase cardiac conduction velocity (CV).
However, few studies have addressed whether targeted IK1 inhibition similarly
affects ventricular electrophysiology. The aim of this study was to determine
the effects of PA-6 on cardiac repolarization and conduction in Langendorff-
perfused guinea pig hearts. PA-6 (200 nm) or vehicle was perfused into
ex-vivo guinea pig hearts for 60 min. Hearts were optically mapped with
di-4-ANEPPS to quantify CV and APD at 90% repolarization (APD90). Ven-
tricular APD90 was significantly prolonged in hearts treated with PA-6
(115  2% of baseline; P < 0.05), but not vehicle (105  2% of baseline).
PA-6 slightly, but significantly, increased transverse CV by 7%. PA-6 signifi-
cantly prolonged APD90 during hypokalemia (2 mmol/L [K+]o), although to a
lesser degree than observed at 4.56 mmol/L [K+]o. In contrast, the effect of
PA-6 on CV was more pronounced during hypokalemia, where transverse CV
with PA-6 (24  2 cm/sec) was significantly faster than with vehicle
(13  3 cm/sec, P < 0.05). These results show that under normokalemic con-
ditions, PA-6 significantly prolonged APD90, whereas its effect on CV was
modest. During hypokalemia, PA-6 prolonged APD90 to a lesser degree, but
profoundly increased CV. Thus, in intact guinea pig hearts, the electrophysio-
logic effects of the IK1 inhibitor, PA-6, are [K+]o-dependent.
Introduction
The inward rectifier potassium current (IK1) is an impor-
tant regulator of the cardiac action potential, serving to
stabilize the resting membrane potential (Sakmann and
Trube 1984; Tourneur 1986), and contributing to late
repolarization (Kass et al. 1990; Ibarra et al. 1991). The
molecular basis of cardiac IK1 is attributed to the Kir2.x
subfamily of inward rectifier potassium channel proteins
(Dhamoon and Jalife 2005), which are strongly regulated
by extracellular potassium concentration ([K+]o). For
instance, hypokalemia is known to shift the reversal
potential for IK1 to a more negative potential and reduce
the slope conductance of the inward current (resulting in
a decreased peak density of IK1), as well as hyperpolarize
the resting membrane potential (Scamps and Carmeliet
1989; Shimoni et al. 1992; Hirota et al. 2000), which
together alters sodium channel availability and cardiac
excitability. Studies have suggested that IK1 plays a critical
role in modulating cardiac excitability and the incidence
of arrhythmias including congenital atrial fibrillation
(Deo et al. 2013), catecholaminergic polymorphic
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ventricular tachycardia (Barajas-Martinez et al. 2011),
ventricular fibrillation (Warren et al. 2003), and arrhyth-
mias associated with Andersen-Tawil syndrome type I
and short QT syndrome 3 (see Anumonwo and Lopatin
(2010) for review). Furthermore, hypokalemia has been
suggested to exacerbate conduction abnormalities, with
reports of an increased risk of ventricular arrhythmias in
Brugada patients (Araki et al. 2003; Notarstefano et al.
2005). Similarly, during hypokalemia patients with Ander-
sen-Tawil syndrome type 1 have more pronounced ECG
changes (Zhang et al. 2005), a greater burden of prema-
ture ventricular contractions (Tawil et al. 1994; Nichols
et al. 1996), and an increased occurrence of ventricular
arrhythmias (Tawil et al. 1994; Tristani-Firouzi et al.
2002). Lastly, in heart failure, which is associated with a
loss of IK1 function (Kaab et al. 1996), both the complex
pathologic state and common therapies can lead to elec-
trolyte disturbances including hypokalemia (Leier et al.
1994). Thus, regulation of IK1 and potassium homeostasis
has significant clinical implications for cardiac conduction
and arrhythmogenesis.
Despite several decades of recognizing the importance
of IK1 for cardiac function, the lack of specific and effica-
cious agonists/antagonists for Kir2.x channels has slowed
progress toward understanding the physiologic and
pathophysiologic roles of IK1 in the heart. Pharmacologic
compounds targeting IK1 generally lack specificity for
Kir2.x channels, or have toxic side effects that prohibit
their use in vivo (de Boer et al. 2010; Bhoelan et al.
2014). Recently, seven analogs of the diamine antiproto-
zoal drug pentamidine were shown to inhibit IK1 at
nanomolar concentrations. The sixth analog (PA-6) was
shown to have high efficiency and specificity for inhibi-
tion of the Kir2.x-mediated current (i.e., IK1) (Takanari
et al. 2013). In isolated cardiac myocytes, PA-6 was previ-
ously shown to increase action potential duration (APD)
(Takanari et al. 2013). Additionally, 200 nm PA-6 pro-
longed APD in ventricular myocardium of isolated rat
hearts (Skarsfeldt et al. 2016).
Previously, we demonstrated that partially inhibiting
IK1 with BaCl2 prolongs ventricular APD and increases
conduction velocity (CV) in ventricular myocardium of
isolated guinea pig hearts (Poelzing and Veeraraghavan
2007; Veeraraghavan and Poelzing 2008), whose action
potential morphology more closely mimics human action
potentials than those of rats and smaller rodents. How-
ever, barium is known to have multiple off-target effects,
which could confound these findings (Lesage et al. 1995).
The aim of this study was to investigate the effects of the
selective IK1 inhibitor, PA-6, on action potential repolariza-
tion and conduction in an intact guinea pig heart prepara-
tion during normo- and hypokalemia. In this study, we
demonstrate that in Langendorff-perfused adult guinea pig
hearts, inhibiting IK1 alone prolongs ventricular repolariza-
tion but does not substantially alter conduction. However,
under hypokalemic conditions, which itself prolongs APD
and decreases CV, treatment with PA-6 resulted in further
APD prolongation and increased CV.
Materials and Methods
Animals
Animal care and experimental procedures were approved
by the Institutional Animal Care and Use Committee at
Virginia Polytechnic Institute and State University and
conducted in compliance with the European convention
for the protection of vertebrate animals used for experi-
mental and other scientific purposes (Council of Europe
No 123, Strasbourg 1985).
Male retired breeder, albino Hartley guinea pigs (Hilltop
Lab Animals, Scottdale, PA; n = 29, approximately 900–
1200 g, 13–20 months old) were placed in an induction
chamber and anesthetized with 5% isoflurane mixed with
100% oxygen at 3 L/min. After losing consciousness, the
animal was removed from the induction chamber and
masked with 3–5% isoflurane mixed with 100% oxygen at
4 L/min. Once in a surgical plane of anesthesia, a thoraco-
tomy was performed, the heart was excised and rinsed in
Tyrode’s solution (see below for details on perfusate com-
position).
Langendorff perfusion
After the heart was excised, the aorta was cannulated and
perfused retrogradely with a modified Tyrode’s solution
containing (in mmol/L): NaCl 140, KCl 4.56, CaCl2 1.25,
dextrose 5.5, MgCl2 0.7, and HEPES 10; pH was adjusted
to 7.40–7.42 at 37°C using NaOH. The Tyrode’s solution
was bubbled with 100% oxygen and perfused at a con-
stant flow to maintain a perfusion pressure of 40–
55 mmHg. The atria were excised to reduce competitive
stimulation, and the heart was placed in a custom-made
tissue bath where it was immersed in the perfusate and
maintained at 37°C. Hearts were stimulated with a unipo-
lar silver chloride wire positioned on the epicardium of
the anterior left ventricle (LV) and paced at a basic cycle
length (BCL) of 300 msec using a pulse width of 5 msec
and current strength at 1.59 the diastolic threshold.
Optical mapping
Cardiac motion was suppressed by adding the electrome-
chanical uncoupler 2,3-butanedione monoxime (BDM,
7.5 mmol/L) to the perfusate. The voltage sensitive dye di-4
ANEPPS (7.5 lmol/L; Biotium, Hayward, CA) was perfused
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into the heart for 10 min followed by a 10 min washout
period before the start of the experimental protocol. Di-4-
ANEPPS was excited by illuminating the anterior surface of
the heart with a 150 W halogen light source (MHAB-
150 W, Moritex Corporation) and quartz fiber light guide
(Moritex Corporation, Saitama, Japan) fitted with an excita-
tion filter (center wavelength of 510/10 nm; Semrock,
Rochester, NY). Fluoresced light was collected by a tandem
lens assembly (0.639 magnification), transmitted through a
610 nm long pass filter (610FG01-50(T257), Andover Cor-
poration, Salem, NH), and detected by a 100 9 100 pixel
CMOS camera (MiCAM Ultima-L, SciMedia, Costa Mesa,
CA) with a field of view of 15.9 9 15.9 mm2 (0.159 mm
interpixel resolution). Fluorescence was recorded at a sam-
pling rate of 1000 frames/sec.
Reagents
Di-4-ANEPPS (5 mg) was dissolved in 1.3 mL of ethanol
to create an 8 mmol/L stock solution. The pentamidine
analog PA-6 (C31H32N4O2) was synthesized by Syngene,
Bangalore, India. PA-6 (M.W. = 492.62) was dissolved in
dimethyl sulfoxide (DMSO) and prepared as a 5 mmol/L
stock solution. PA-6 is known to interact with the cyto-
plasmic domain of Kir2.1 (Takanari et al. 2013), and data
from rat hearts suggest that maximal, stable effects of PA-
6 occur between 45 and 90 min of exposure (Skarsfeldt
et al. 2016). To maintain PA-6 in solution and facilitate
intracellular uptake over a sustained period, at the time
of the experiment, 40 lL of the PA-6 stock solution was
mixed with 40 lL of Pluronic solution (1 g of Pluronic
F-127, Sigma-Aldrich, dissolved in 5 mL of DMSO) and
added to 1 L of Tyrode’s solution for a final PA-6 con-
centration of 200 nmol/L. For vehicle control (Veh) stud-
ies, 40 lL of DMSO and 40 lL of Pluronic solution were
added to 1 L of Tyrode’s solution.
Experimental protocol
After the Di-4-ANEPPS washout period, steady-state opti-
cal action potentials were recorded at baseline, and after
30 and 60 min of no treatment (time control, TC, n = 3)
or treatment with either PA-6 (200 nmol/L, n = 8) or
Veh (DMSO + Pluronic, n = 5). In separate studies (PA-
6: n = 9, vehicle: n = 4), hearts were perfused with Tyr-
ode’s solution containing 2 mmol/L [K+] (vs. 4.56 mmol/
L) and the experimental protocol was performed as
described above.
Data analysis
Fluorescence signals were binned 2 9 2, yielding an effec-
tive spatial resolution of 0.318 mm. Action potential
activation times and 90% repolarization times were quan-
tified as previously described (Girouard et al. 1996; Tian
et al. 2004). APD at 90% repolarization (APD90) was cal-
culated as the difference between the 90% repolarization
and activation times. CV was quantified from contour
maps of activation times transverse (CVT) and longitudi-
nal (CVL) to fiber orientation as previously described
(Entz et al. 2016). All data are presented as mean  stan-
dard error of the mean. Two-tailed, paired Student’s
t-tests were used to compare mean APD90, CVT, and CVL
after treatment to corresponding baseline values within
the same heart. Two-tailed, unpaired Student’s t-tests
were used to compare means between groups at a given
time point. Differences were considered to be statistically
significant for P < 0.05.
Results
Action potential prolongation with PA-6
inhibition of IK1
To investigate the effects of IK1 inhibition on ventricular
repolarization, Langendorff-perfused guinea pig hearts
were treated with 200 nmol/L PA-6 for 60 min and
APD90 was measured from optical action potentials
recorded at 0 (pretreatment), 30, and 60 min. The results
from PA-6 treated hearts (n = 8) were compared to time
(TC, n = 3) and vehicle control hearts (Veh, n = 5) to
assess the effects of preparation stability and the vehicle
solvent (DMSO + Pluronic) on APD90. Shown in Fig-
ure 1A are superimposed action potentials from the same
recording pixel at baseline (0 min) and 60 min for each
treatment group: time control (TC), vehicle (Veh), and
PA-6. These traces demonstrate that over 60 min, the
action potentials recorded in the time control and vehicle
hearts were relatively unchanged. In contrast, there were
marked changes in the action potential obtained after
60 min of treatment with PA-6 (Fig. 1A, bottom). Specifi-
cally, PA-6 appeared to affect late repolarization (phase 3
of the action potential), resulting in a prolonged action
potential duration (ΔAPD90 = 34 msec). Over all experi-
ments (n = 8), PA-6 significantly prolonged APD90
(Fig. 1B) at both 30 (Δ14.2 msec, 108.7% of baseline,
P < 0.05) and 60 min (Δ22.3 msec, 113.6% of baseline,
P < 0.05) of treatment. Over the course of 60 min, a
small (Δ5.7 msec, 103.4% of baseline) but statistically sig-
nificant APD90 prolongation was observed in untreated
hearts (TC). At 60 min, APD90 in PA-6 treated hearts
was significantly longer than both Veh and TC hearts.
There were no significant differences in APD90 between
Veh and TC at any of the time points. These data
demonstrate that PA-6 increases APD90 independent of
any effects due to time or exposure to vehicle.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Negligible effect of PA-6 on conduction
velocity
We previously demonstrated that 10 lmol/L BaCl2 can
increase cardiac conduction (Veeraraghavan and Poelzing
2008). In order to assess the effect of a more potent and
specific inhibitor of IK1 on transverse and longitudinal con-
duction, CVT and CVL were measured before and after
treatment with 200 nmol/L PA-6 during normokalemia
([K+] = 4.56 mmol/L). Representative maps of activation
isochrones are presented in Figure 2A. These maps demon-
strate that after 60 min, there was very little change in the
activation patterns due to time (TC) or treatment with
Veh or PA-6. Summary data of CV (CVT and CVL)
revealed a very modest effect of inhibiting IK1 on conduc-
tion (Fig. 2B). Specifically, treatment with 200 nmol/L PA-
6 modestly, but significantly, increased CVT by paired
comparison from 21.9  1.2 to 23.4  1.1 cm/sec at
30 min (P < 0.05) and 23.4  1.2 cm/sec at 60 min
(P = 0.05). However, PA-6 did not increase conduction
relative to TC or Veh, as determined by unpaired statistical
comparisons. Hence, neither CVT nor CVL were signifi-
cantly different in hearts treated with PA-6 compared to
TC and Veh-treated hearts at any time point.
IK1 inhibition during hypokalemia
Lowering [K+]o leads to a decrease in IK1 peak current
density (Scamps and Carmeliet 1989), as well as changes
in resting membrane potential and excitability (Shimoni
et al. 1992). Previously, we demonstrated that hypokale-
mia differentially modulates ventricular myocardial elec-
trophysiology during partial IK1 blockade with 10 lmol/L
BaCl2 (Poelzing and Veeraraghavan 2007). Therefore, we
sought to test the effect of PA-6 on repolarization and
conduction during conditions of hypokalemia. Isolated
hearts were equilibrated in Tyrode’s solution containing
2 mmol/L [K+]o, and the experimental protocol was
repeated as before with 200 nmol/L PA-6 (n = 9) and
Veh (n = 4). At baseline, hypokalemia by itself prolonged
APD90 (202.4  5.3 compared to 164.1  1.9 msec at
4.56 mmol/L [K+]o, P < 0.05) and decreased CVT
(18.0  1.8 compared to 23.1  0.7 cm/sec at 4.56
mmol/L [K+]o, P < 0.05) and CVL (37.0  2.7 compared
to 54.0  1.4 cm/sec at 4.56 mmol/L [K+]o, P < 0.05).
Representative action potentials in Figure 3A demon-
strate the action potential changes induced by PA-6 dur-
ing hypokalemia. While the action potential at baseline
(0 min) is already longer than the corresponding action
potentials in Figure 1A due to reduced [K+]o, subse-
quent treatment with 200 nmol/L PA-6 resulted in fur-
ther prolongation of APD90. In contrast, the action
potentials from Veh-treated hearts were nearly superim-
posable, with no discernable effect on repolarization.
The time-dependent effects of PA-6 on APD90 during
hypokalemia are summarized in Figure 3B. Within
30 min, PA-6 significantly increased APD90 (Δ13.9 msec,
109.3% of baseline, P < 0.05) and the prolongation
Figure 1. PA-6 prolongs APD90 in normokalemic hearts. (A) Superimposed action potentials at 0 min (pretreatment) and after 60 min of time
control (TC), or treatment with vehicle (Veh) or 200 nmol/L PA-6 at [K+]o = 4.56 mmol/L. The difference in APD90 values are shown as ΔAPD in
the inset. (B) Summary data of mean APD90 (top) and the change in APD90 (as a percent of baseline, bottom) over 60 min in each of the three
treatment groups. *P < 0.05 versus Veh, #P < 0.05 versus baseline.
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persisted up to 60 min (Δ8.9 msec, 106.9% of baseline,
P < 0.05). This APD prolongation (as a percent change
from baseline) was significantly less than that observed
after 60 min of PA-6 treatment with 4.56 mmol/L [K+]o
(6.9% vs. 13.6%, P < 0.05). The reduced effect of PA-6
on APD prolongation during hypokalemia could possibly
be due to partial inhibition of IK1 by the lowered [K
+]o
prior to application of PA-6. There were no significant
differences in APD90 in Veh-treated hearts at either 30
or 60 min.
Comparing the representative baseline (0 min) activa-
tion maps at 2 mmol/L [K+]o (Fig. 4A) to those at
4.56 mmol/L [K+]o (Fig. 2A), it is apparent that there is
crowding of isochrones during hypokalemia representing
slower conduction due to the decrease in [K+]o. The pat-
tern of activation and number of isochrones was relatively
unchanged by 60 min of treatment with Veh. In contrast,
the activation map after 60 min of PA-6 revealed a
marked effect on conduction, with far fewer isochrones
(total activation time = 34 msec vs. 42 msec at baseline)
and a corresponding increase in CV. In fact, the summary
data presented in Figure 4B shows that for all experi-
ments PA-6 reversed the decrease in CVT that was
observed with hypokalemia, and restored CVT to values
observed under normakalemia (23.6  2.4 cm/sec vs.
23.1  0.7 cm/sec). Mean CVT was greater with PA-6
than Veh at both 30 min (23.3  1.9 cm/sec vs.
14.1  2.7 cm/sec, P < 0.05) and 60 min (23.6  2.4
cm/sec vs. 12.6  3.4 cm/sec, P < 0.05). A similar trend
was observed for CVL, where mean CVL after 30 minutes
of treatment with PA-6 was 45.4  3.3 cm/sec (compared
to Veh: 34.4  4.6, P = 0.08) and after 60 min CVL
was 44.3  3.6 cm/sec (compared to Veh: 29.8  7.9,
P = 0.09).
Figure 2. Effect of PA-6 on CV in normokalemic hearts. (A) Representative contour maps of action potential activation times at 0 min
(pretreatment) and 60 min of time control (TC), or treatment with vehicle (Veh) or 200 nmol/L PA-6 at [K+]o = 4.56 mmol/L. Each isochrone
represents a 3 msec change in activation time. The pacing symbol at the center of each map indicates the site of stimulus delivery. (B)
Summary data of mean CVT (top) and CVL (bottom) over 60 min in each of the three treatment groups. *P < 0.05 versus Veh,
#P < 0.05
versus baseline.
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Discussion
Recently, selective inhibition of IK1 with the pentamidine
analog PA-6 was shown to influence action potential
repolarization and refractoriness in isolated rat hearts
(Skarsfeldt et al. 2016). Prior to the development of
PA-6, our laboratory demonstrated that inhibiting IK1
with BaCl2 led to APD prolongation(Poelzing and Veer-
araghavan 2007) and enhanced conduction(Veeraraghavan
and Poelzing 2008) in Langendorff-perfused guinea pig
hearts. In this study, using the same experimental model,
we found that 60 min of treatment with 200 nmol/L PA-
Figure 3. PA-6 prolongs APD90 in hypokalemic hearts. (A) Superimposed action potentials at 0 min (pretreatment) and after 60 min of
treatment with vehicle (Veh) or 200 nmol/L PA-6 at [K+]o = 2 mmol/L. The difference in APD90 values are shown as ΔAPD in the inset. (B)
Summary data of mean APD90 (left) and the change in APD90 (as a percent of baseline, right) over 60 min during treatment with PA-6 or Veh.
*P < 0.05 versus Veh, #P < 0.05 versus baseline.
Figure 4. PA-6 increases CV in hypokalemic hearts. (A) Representative contour maps of action potential activation times at 0 min
(pretreatment) and 60 min of treatment with vehicle (Veh) or 200 nmol/L PA-6 at [K+]o = 2 mmol/L. Each isochrone represents a 3 msec
change in activation time. The pacing symbol at the center of each map indicates the site of stimulus delivery. (B) Summary data of mean CVT
(top) and CVL (bottom) over 60 min in each of the three treatment groups. *P < 0.05 versus Veh,
#P < 0.05 versus baseline.
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6: (1) significantly prolonged ventricular APD90; (2) had
minimal to no effect on CVT or CVL during normokale-
mia; (3) prior to administration of PA-6, hypokalemia
(2 mmol/L [K+]o) significantly prolonged APD90 and
decreased CVT and CVL; (4) during hypokalemia, PA-6
prolonged APD90 further; and (5) in contrast to normo-
kalemia, treatment with PA-6 during hypokalemia signifi-
cantly increased CVT and demonstrated a similar trend in
CVL.
A role for IK1 in cardiac repolarization has been demon-
strated by studies conducted in a number of species, using
a variety of pharmacologic agents to inhibit Kir2.x [e.g.
BaCl2 (Poelzing and Veeraraghavan 2007; Wu et al. 1999;
Baiardi et al. 2003), MS-551 (Nakaya et al. 1993; Sen et al.
1998) RP58866 (Rees and Curtis 1993), RP62719 (Wil-
liams et al. 1999; Biliczki et al. 2002), chloroquine (Nou-
jaim et al. 2010), tamoxifen (He et al. 2003), carbon
monoxide (Liang et al. 2014), and cesium (Morita et al.
2007)]. Related studies have consistently found that
inhibiting IK1 prolongs the QT interval and APD, although
the severity of the effect varies widely (Rees and Curtis
1993; Biliczki et al. 2002; He et al. 2003). Among these
studies, those reporting the largest effect on APD predomi-
nantly utilized nonselective compounds or doses of inhibi-
tors that are known to be nonselective for IK1. Thus, it is
possible that nonspecific effects influenced these findings,
and that they represent an overestimation of the role of IK1
in normal cardiac repolarization.
In Langendorff-perfused guinea pig hearts, we found
that 60 min of treatment with 200 nmol/L PA-6, a dose
which has been shown to inhibit IK1 by 77–100% while
having no effect on INa, ICa, Ito, IKr, or IKs (Takanari et al.
2013), prolonged APD90 by 14%. Previously, 200 nmol/L
PA-6 was shown to increase APD90 by 74% in Langen-
dorff-perfused rat hearts (Skarsfeldt et al. 2016). However,
it is difficult to directly compare APD prolongation from
studies in rat hearts to those of humans and other larger
mammals with more pronounced action potential pla-
teaus, as the composition and time course of their respec-
tive repolarizing currents are clearly distinct from one
another. As a result, APD90 in ventricular guinea pig myo-
cardium is fourfold longer than in rat at baseline condi-
tions [164 msec vs. 42 msec (Skarsfeldt et al. 2016)].
Interestingly, the absolute change in mean APD90 induced
by PA-6 was similar in the two species (22.3 msec in gui-
nea pig, 30.8 msec in rat). However, since late repolariza-
tion (where IK1 is active) constitutes a greater percentage
of total APD in rat than guinea pig, the resulting percent
difference in APD prolongation for a given absolute
change is much larger in rat myocardium. A review of the
literature supports the assertion that APD prolongation
due to IK1 inhibition is enhanced in species with no action
potential plateau (e.g., rat and mouse) relative to species
with an action potential plateau (e.g., guinea pig, rabbit,
canine, primate, and human) (Rees and Curtis 1993; Wil-
liams et al. 1999; Baiardi et al. 2003; Noujaim et al. 2010;
Nagy et al. 2013). Accordingly, in isolated canine adult-
ventricular cardiomyocytes, 200 nmol/L PA-6 increased
APD90 by 34% (Takanari et al. 2013), which is similar to
our findings in guinea pig. Using arguably the most com-
monly used approach for inhibiting IK1 (i.e., 10 lmol/L
BaCl2), we previously observed a 15–25% prolongation of
APD in isolated guinea pig hearts, similar to the effect we
are currently reporting with PA-6. Thus, in larger mam-
mals with action potential morphologies similar to those
in human, the effect of PA-6 on cardiac repolarization
appears to be less than observed in smaller rodent species
which lack a prominent plateau.
Given that IK1 plays a critical role in determining the
resting membrane potential, it has been postulated that
IK1 could oppose the depolarizing current through volt-
age-gated sodium channels (i.e. INa) during the early
phase of AP activation. Consequently, inhibiting IK1
would lead to an increase in cardiac CV. Alternatively,
decreased IK1 could potentially raise the resting mem-
brane potential, resulting in sodium channel inactivation,
thereby leading to a decrease in CV. However, the effect
on the ventricular resting membrane potential following
IK1 blockade has in most studies has been found to be
either minor or undetectable, suggesting a resting mem-
brane potential reserve of other potassium currents (see
van der Heyden and Jespersen (2016) for review). Despite
a well-recognized role for IK1 modulation of cardiac
excitability, surprisingly few studies have directly tested
the prevailing theories of the effect of IK1 inhibition on
ventricular conduction. Escande et al. (1992) saw no
change in CV with RP62719, while Noujaim et al. (2010)
reported a 35% decrease in CV with chloroquine. How-
ever, both of these IK1 inhibitors have been demonstrated
to block other potassium currents at the doses tested, as
well as sodium and calcium currents in the case of
chloroquine (Jurkiewicz et al. 1996; Yang et al. 1999;
Fujita and Kurachi 2000). In support of the theory that
IK1 opposes INa depolarization, we have previously
reported that 10 lmol/L BaCl2 increased CVT by approxi-
mately 25% (+6 cm/sec) (Veeraraghavan and Poelzing
2008). The corresponding increase in CVT in this study
with 200 nmol/L PA-6 was 7% (+1.5 cm/sec). This is
consistent with a lack of an effect of 200 nmol/L PA-6 on
resting membrane potential in isolated canine cardiomy-
ocytes (Takanari et al. 2013). Altogether, this suggests
that less specific IK1 inhibitors, such as BaCl2, may alter
CV due to off-target effects, and/or on its own, selective
inhibition of IK1 can significantly impact repolarization,
but alone may not be sufficient to change cardiac
excitability or appreciably alter CV.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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To further compare our findings with PA-6 to those
with BaCl2, we repeated the experimental protocol under
conditions of low [K+]o. Consistent with previous results
(Poelzing and Veeraraghavan 2007), lowering [K+]o to
2 mmol/L prolonged APD by approximately 25%. Treat-
ment with 200 nmol/L PA-6 prolonged APD by a further
4–7%. Importantly, hypokalemia alone significantly
decreased CVT by 22%, whereas subsequent treatment
with PA-6 increased CVT by 27%, effectively reversing the
conduction loss due to hypokalemia and restoring CVT to
normokalemic values (23.6 cm/sec vs. 23.1 cm/sec). To
our knowledge, this is the first study to investigate the
effects of IK1 inhibition on cardiac conduction under con-
ditions of hypokalemia. Therefore, these data suggest that
PA-6 may actually rescue conduction slowing induced by
hypokalemia. Lowering [K+]o will hyperpolarize the rest-
ing membrane potential, leading to a delay in sodium
channel activation and therefore a slowing of conduction.
Subsequent IK1 blockade could potentially depolarize the
membrane and restore normal resting membrane poten-
tial, thereby alleviating the conduction abnormality
induced by hypokalemia. Which leads to the question—
why does not PA-6 not increase CV at normokalemia?
Perhaps cardiomyocyte excitability is more sensitive to
small shifts (a few mV) in membrane potential at more
hyperpolarized potentials than at normal resting mem-
brane potential. Alternatively, perhaps IK1 inhibition alone
is insufficient to significantly affect resting membrane
potential or CV, and a further perturbation, such as hypo-
kalemia, is required before an effect is observed. Data from
Takanari et al. (2013) would support the latter, given that
no change in resting membrane potential was observed in
isolated canine cardiomyocytes treated with 200 nmol/L
PA-6. Lastly, it is possible that PA-6 inhibition of IK1 is
[K+]-dependent. It has been demonstrated that permeant
ions (in this case K+) can influence ligand interactions
with ion channels (Zhorov and Tikhonov 2013), and per-
haps the greater effect of PA-6 on CV at low [K+]o could
be explained by such an interaction. These provocative
hypotheses warrant further testing, particularly as new
small molecule IK1 inhibitors such as ML133 are being
developed for use in vivo (Wang et al. 2011).
Limitations
Due to the degradation of di-4-ANEPPS fluorescence sig-
nals over time, we limited our experimental protocol to
60 min of PA-6 treatment. While PA-6 has been demon-
strated to have a stable effect on APD90 within 45 min of
treatment in Langendorff-perfused rat hearts, the ventric-
ular effective refractory period increased up to 90 min
(Skarsfeldt et al. 2016). Therefore, it is possible that
longer exposure times could reveal more pronounced
effects of IK1 inhibition than observed in this study. While
the specificity of PA-6 for IK1 has been rigorously tested
in heterologous systems expressing cardiac ion channels
from human and mouse, as well as in isolated canine car-
diomyocytes (Takanari et al. 2013), specificity has not
been tested in guinea pig cardiomyocytes.
Conclusion
Under normokalemic conditions, the IK1 inhibitor PA-6
significantly prolonged APD90 without substantially affect-
ing CV. During hypokalemia, PA-6 prolonged APD90,
although to a lesser degree, and significantly increased
CV. Thus, in isolated guinea pig hearts, the electrophysio-
logic effects of PA-6 are [K+]o-dependent. Furthermore,
these results highlight the importance of using a selective
inhibitor to investigate the role of IK1 in cardiac repolar-
ization and conduction, as well as validating these results
in a species with action potential morphologies similar to
those in human. Given its superior selectivity for IK1 and
advantageous safety profile, PA-6 will serve as an impor-
tant tool for advancing our understanding of the physio-
logic and pathophysiologic roles of IK1 in vivo.
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